Vapotherm said today that it launched its next-gen Precision Flow Hi-VNI system intended to relieve respiratory stress in spontaneously breathing patients.
The Exeter, N.H.-based company touted that the next-gen device features improvements to both its software and hardware intended to improve reliability.
The Precision Flow Hi-VNI system is designed to deliver maskless noninvasive ventilation to patients who are spontaneously breathing to relieve respiratory distress including hypercapnia, hypoxemia and dyspnea, Vapotherm said.
The company’s Precision Flow devices are intended to provide high-velocity heated, humidified and oxygenated air to treat patients with conditions such as pneumonia, chronic obstructive pulmonary disease, asthma and heart failure.
“We’re excited to offer this next generation of the Precision Flow system to our customers. We remain dedicated to continuous improvement in the products and services we offer our customers and patients and these improvements deliver on that commitment,” CEO Joe Army said in a press release.
Last December, data from a clinical trial indicated that Vapotherm’s IntellO2 module for its Precision Flow system greatly improved the chances of keeping premature babies in the target oxygenation range.
